1. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D’Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA and Freedman-Cass DA. NCCN guidelines(R) insights: prostate cancer, version 1.2023. J Natl Compr Canc Netw 2022; 20: 1288-1298.
2. Time trends and local variation in primary treatment of localized prostate cancer;MR;J Clin Oncol,2010
3. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.
4. Intermediate endpoints after postprostatectomy radiotherapy: 5-year distant metastasis to predict overall survival;Jackson;Eur Urol,2018
5. Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M, Graefen M, Marchioro G, Frohneberg D, Giona S, Karakiewicz PI, Van Poppel H, Montorsi F and Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Natural history of surgically treated high-risk prostate cancer. Urol Oncol 2015; 33: 163, e7-13.